Back to Search
Start Over
Gene expression assay in the management of early breast cancer
- Publication Year :
- 2020
- Publisher :
- Bentham Science Publishers, 2020.
-
Abstract
- The addition of adjuvant chemotherapy to hormonal therapy is often considered questionable in patients with estrogen receptor-positive early breast cancer. Low risk of disease relapse after endocrine treatment alone and/or a low sensitivity to chemotherapy are reasons behind not all patients benefit from chemotherapy. Most of the patients could be exposed to unnecessary treatment- related adverse events and health care costs when treatment decision-making is based only on classical clinical histological features. Gene expression profile has been developed to refine physician’s decision-making process and to tailor personalized treatment to patients. In particular, these tests are designed to spare patients the side effects of unnecessary treatment, and ensure that adjuvant chemotherapy is correctly recommended to patients with early breast cancer. In this review, we will discuss the main diagnostic tests and their potential clinical applications (Oncotype DX, MammaPrint, PAM50/Prosigna, EndoPredict, MapQuant Dx, IHC4, and Theros-Breast Cancer Gene Expression Ratio Assay).
- Subjects :
- Oncology
medicine.medical_treatment
Biochemistry
PAM50/Prosigna
Oncotype DX
0302 clinical medicine
MammaPrint
Drug Discovery
Health care
Receptors
Gene Expression Assay
Adjuvant
0303 health sciences
MapQuant Dx
medicine.diagnostic_test
Management of Early Breast Cancer
Gene Expression Regulation, Neoplastic
Receptors, Estrogen
Local
Chemotherapy, Adjuvant
MammaPrint dx
030220 oncology & carcinogenesis
Molecular Medicine
Hormonal therapy
medicine.medical_specialty
medicine.drug_class
Breast Neoplasms
+
)
03 medical and health sciences
Adjuvant chemotherapy
Early breast cancer (EBC)
Estrogen receptor positive (ER
Diagnostic Tests, Routine
Gene Expression Profiling
Humans
Neoplasm Recurrence, Local
Diagnostic Tests
Internal medicine
Breast Cancer
medicine
Endocrine system
Chemotherapy
Routine
Adverse effect
030304 developmental biology
Pharmacology
Neoplastic
business.industry
Organic Chemistry
Estrogen
Neoplasm Recurrence
Gene Expression Regulation
business
Subjects
Details
- Language :
- English
- Database :
- OpenAIRE
- Accession number :
- edsair.doi.dedup.....8ce84b8979e0a4a79cc3feb660a405ac